Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of MSB11022 versus Humira in moderately to severely active rheumatoid arthritis
2016-002852-26Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of idacio in rheumatoid arthritis (RA) (2 arms), sponsored by Merck KGaA. Primary endpoint: Incidence of adverse events including and up to Week 52. Started Sep 2016; status: completed.
02
Drugs
idacio
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-002852-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002852-26.